Heart Failure

This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies. The main focus of this book is to review current and emerging heart failure therapies and potential targets for treatment.

1133096030
Heart Failure

This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies. The main focus of this book is to review current and emerging heart failure therapies and potential targets for treatment.

369.0 In Stock

eBook1st ed. 2017 (1st ed. 2017)

$369.00 

Available on Compatible NOOK devices, the free NOOK App and in My Digital Library.
WANT A NOOK?  Explore Now

Related collections and offers


Overview

This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies. The main focus of this book is to review current and emerging heart failure therapies and potential targets for treatment.


Product Details

ISBN-13: 9783319596594
Publisher: Springer International Publishing
Publication date: 06/09/2017
Series: Handbook of Experimental Pharmacology , #243
Sold by: Barnes & Noble
Format: eBook
Pages: 581
File size: 3 MB

Table of Contents

Introduction.- Epidemiology.- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine.- Beta3 agonists.- Novel MRAs.- pGCs and Natriuretic peptides.- sGC stimulators.- PDE’s.- Adenosin and A1 Agonists.- Myosin heavy chain / Troponin.- Stem cells.- Diuretics and Vasopressin.- GeneTherapy.- RNA-based therapies and micro RNAs.- Cardiac myosin activation using gene therapy.- Bendavia – mitochondrial therapies.- WNT signaling.- Anticoagulation therapy and NOACS in HF.- Potassium Binders.- Iron.           
From the B&N Reads Blog

Customer Reviews